Semaglutide is an innovative medication offered at Dripsy IV Bar to help control high blood sugar in adults with type 2 diabetes mellitus. It belongs to the class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, which are essential for regulating blood sugar levels by activating the GLP-1 receptor.

At Dripsy IV Bar, Semaglutide is available as an injectable solution administered once a week or as an oral solution administered under the tongue once daily. Semaglutide has shown remarkable results in weight loss, with many individuals experiencing up to a 15% decrease in weight within just four months of starting treatment.

• Appetite Regulation: Semaglutide mimics the natural hormone GLP-1, which is involved in appetite control. By activating GLP-1 receptors in the brain, it helps reduce hunger and lower calorie intake.
• Delayed Gastric Emptying: It slows the rate at which food leaves the stomach, leading to a prolonged feeling of fullness.
• Glucose-Dependent Insulin Secretion: Semaglutide enhances insulin secretion when blood glucose levels are high, improving blood sugar control and reducing the risk of hypoglycemia.
• Glucagon Suppression: It suppresses the release of glucagon, a hormone that raises blood sugar levels, thereby helping to lower blood glucose in individuals with diabetes.
• Energy Expenditure and Lipid Metabolism: Semaglutide may increase energy expenditure and promote fat burning, which can lead to weight loss and improvements in cholesterol and triglyceride levels.
• Stronger Metabolism: Boosts metabolic rate, leading to increased energy levels.
• Improved Bone Density: Contributes to healthier bones and reduced risk of osteoporosis.